171 related articles for article (PubMed ID: 31401124)
41. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
42. Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences.
Wendt FR; Sajantila A; Moura-Neto RS; Woerner AE; Budowle B
Int J Legal Med; 2018 Jul; 132(4):1007-1024. PubMed ID: 29075918
[TBL] [Abstract][Full Text] [Related]
43. CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels.
Ray B; Ozcagli E; Sadee W; Wang D
Pharmacogenet Genomics; 2019 Feb; 29(2):39-47. PubMed ID: 30520769
[TBL] [Abstract][Full Text] [Related]
44. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
45. Novel variant of CYP2D6*6 is undetected by a commonly used genotyping procedure.
Rasmussen HB; Werge T
Pharmacol Rep; 2011; 63(5):1264-6. PubMed ID: 22180372
[TBL] [Abstract][Full Text] [Related]
46. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
[TBL] [Abstract][Full Text] [Related]
47. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
48. Pharmacogenetic testing revisited: 5' nuclease real-time polymerase chain reaction test panels for genotyping
Larsen JB; Rasmussen JB
Pharmgenomics Pers Med; 2017; 10():115-128. PubMed ID: 28458572
[TBL] [Abstract][Full Text] [Related]
49. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR.
Gaedigk A; Twist GP; Leeder JS
Pharmacogenomics; 2012 Jan; 13(1):91-111. PubMed ID: 22111604
[TBL] [Abstract][Full Text] [Related]
50. CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification: Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele.
Gaedigk A; Riffel AK; Leeder JS
J Mol Diagn; 2015 Nov; 17(6):740-8. PubMed ID: 26335396
[TBL] [Abstract][Full Text] [Related]
51. Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing.
Buermans HP; Vossen RH; Anvar SY; Allard WG; Guchelaar HJ; White SJ; den Dunnen JT; Swen JJ; van der Straaten T
Hum Mutat; 2017 Mar; 38(3):310-316. PubMed ID: 28044414
[TBL] [Abstract][Full Text] [Related]
52. Multiallelic synthetic quality control material: lessons learned from the cystic fibrosis external quality assessment scheme.
Berwouts S; Christensen TM; Brandon J; Bejjani BA; Barton DE; Dequeker E
Genet Test Mol Biomarkers; 2011 Sep; 15(9):579-86. PubMed ID: 21476898
[TBL] [Abstract][Full Text] [Related]
53. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
54. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
55. SNP genotyping using TaqMan technology: the CYP2D6*17 assay conundrum.
Gaedigk A; Freeman N; Hartshorne T; Riffel AK; Irwin D; Bishop JR; Stein MA; Newcorn JH; Jaime LK; Cherner M; Leeder JS
Sci Rep; 2015 Mar; 5():9257. PubMed ID: 25788121
[TBL] [Abstract][Full Text] [Related]
56. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
[TBL] [Abstract][Full Text] [Related]
57. High-throughput analysis of informative CYP2D6 compound haplotypes.
Fletcher B; Goldstein DB; Bradman AL; Weale ME; Bradman N; Thomas MG
Genomics; 2003 Feb; 81(2):166-74. PubMed ID: 12620394
[TBL] [Abstract][Full Text] [Related]
58. Development of an Inexpensive and Rapid Operation Device for High-Throughput Real-Time Quantitative PCR-Based CYP2D6 CNV Genotyping.
Imai M; Kisoi M; Moritsugu M; Murata S; Ichikawa A; Kinoshita K
Biol Pharm Bull; 2019; 42(10):1761-1765. PubMed ID: 31582664
[TBL] [Abstract][Full Text] [Related]
59. Practical interpretation of CYP2D6 haplotypes: Comparison and integration of automated and expert calling.
Ruaño G; Kocherla M; Graydon JS; Holford TR; Makowski GS; Goethe JW
Clin Chim Acta; 2016 May; 456():7-14. PubMed ID: 26908082
[TBL] [Abstract][Full Text] [Related]
60. Validated Reference Panel from Renewable Source of Genomic DNA Available for Standardization of Blood Group Genotyping.
Volkova E; Sippert E; Liu M; Mercado T; Denomme GA; Illoh O; Liu Z; Rios M;
J Mol Diagn; 2019 May; 21(3):525-537. PubMed ID: 30872185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
